Promoter methylation of AREG, HOXA11, hMLH1, NDRG2, NPTX2 and Tes genes in glioblastoma

Journal of Neuro-Oncology

Volumn 113, Issue 3, 2013, Pages 441-449

  Skiriutė, Daina ^a   Vaitkienė, Paulina ^a   Ašmonienė, Virginija ^a   Steponaitis, Giedrius ^a   Deltuva, Vytenis Pranas ^a   Tamašauskas, Arimantas ^a  

^a LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

Author keywords

AREG; DNA methylation; Glioblastoma; HOXA11; MGMT; MS PCR; NDRG2; Survival

Indexed keywords

AMPHIREGULIN; GENOMIC DNA; MESSENGER RNA; MYC PROTEIN; NEURONAL PENTRAXIN II; PENTRAXIN; PROTEIN MLH1; TESTIS DETERMINING FACTOR; TRANSCRIPTION FACTOR HOXA11; TUMOR DNA; UNCLASSIFIED DRUG; AREG PROTEIN, HUMAN; C REACTIVE PROTEIN; CYTOSKELETON PROTEIN; EPIDERMAL GROWTH FACTOR DERIVATIVE; GLYCOPROTEIN; HOMEODOMAIN PROTEIN; HOXA11 PROTEIN, HUMAN; LIM PROTEIN; MLH1 PROTEIN, HUMAN; NDRG2 PROTEIN, HUMAN; NERVE PROTEIN; NEURONAL PENTRAXIN; NUCLEAR PROTEIN; SIGNAL PEPTIDE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TES PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGE; AGED; AREG GENE; ARTICLE; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CELL INVASION; CELL PROLIFERATION; CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; GLIOBLASTOMA; HMLH1 GENE; HOXA11 GENE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NDRG2 GENE; NPTX2 GENE; ONCOGENE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIOTHERAPY; SURVIVAL TIME; TES GENE; TUMOR SUPPRESSOR GENE; BRAIN TUMOR; FOLLOW UP; GENETICS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROMOTER REGION; SURVIVAL RATE; VERY ELDERLY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; AMPHIREGULIN; BRAIN NEOPLASMS; C-REACTIVE PROTEIN; CYTOSKELETAL PROTEINS; DNA METHYLATION; EGF FAMILY OF PROTEINS; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; GLYCOPROTEINS; HOMEODOMAIN PROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIM DOMAIN PROTEINS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84879415256     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1133-3     Document Type: Article

References (39)

1. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, Sabel M, Steinbach JP, Heese O, Reifenberger G, Weller M, Schackert G, German Glioma Network (2007) Long-term survival with glioblastoma multiforme. Brain 130:2596-2606
2. Martinez R, Martin-Subero JI, Rohde V, Kirsch M, Alaminos M, Fernandez AF (2009) A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics 4:255-264
3. Rahnenfuhrer J, Beerenwinkel N, Schulz WA, Hartmann C, von Deimling A, Wullich B, Lengauer T (2005) Estimating cancer survival and clinical outcome based on genetic tumor progression scores. Bioinformatics 10:2438-2446
4. Poplawski T, Tomaszewska K, Galicki M, Morawiec Z, Blasiak J (2008) Promoter methylation of cancer-related genes in gastric carcinoma. Exp Oncol 30:112-116
5. Etcheverry A, Aubry M, de Tayrac M, Vauleon E, Boniface R, Guenot F, Saikali S, Hamlat A, Riffaud L, Menei P, Quillien V, Mosser J (2010) DNA methylation in glioblastoma: impact on gene expression and clinical outcome. BMC Genomics 11:701
6. Laffaire J, Everhard S, Idbaih A, Criniere E, Marie Y, de Reynies A, Schiappa R, Mokhtari K, Hoang-Xuan K, Sanson M, Delattre JY, Thillet J, Ducray F (2011) Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. Neuro Oncol 13:84-98
7. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RGW, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, Wilson RK, Van Den Berg D, Shen H, Bengtsson H, Neuvial P, Cope LM, Buckley J, Herman JG, Baylin SB, Laird PW, Aldape K (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510-522
8. Mueller W, Nutt CL, Ehrich M, Riemenschneider MJ, von Deimling A, van den Boom D, Louis DN (2007) Downregulation of RUNX3 and TES by hypermethylation in glioblastoma. Oncogene 26:583-593
9. Gomori E, Pal J, Meszaros I, Doczi T, Matolcsy A (2007) Epigenetic inactivation of the hMLH1 gene in progression of gliomas. Diagn Mol Pathol 16:104-107
10. Tepel M, Roerig P, Wolter M, Gutmann DH, Perry A, Reifenberger G, Riemenschneider MJ (2008) Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. Int J Cancer 123:2080-2086
11. Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger P, Jouvet A, Scheithauer B, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109
12. Ali AH, Kondo K, Namura T, Senba Y, Takizawa H, Nakagawa Y, Toba H, Kenzaki K, Sakiyama S, Tangoku A (2011) Aberrant DNA methylation of some tumor suppressor genes in lung cancers from workers with chromate exposure. Mol Carcinog 50:89-99
13. Piepoli A, Cotugno R, Merla G, Gentile A, Augello B, Quitadamo M, Merla A, Panza A, Carella M, Maglietta R, D'Addabbo A, Ancona N, Fusilli S, Perri F, Andriulli A (2009) Promoter methylation correlates with reduced NDRG2 expression in advanced colon tumour. BMC Med Genomics 2:11
14. Ma H, Weng D, Chen Y, Huang W, Pan K, Wang H, Sun J, Wang Q, Zhou Z, Wang H, Xia J (2010) Extensive analysis of D7S486 in primary gastric cancer supports TESTIN as a candidate tumor suppressor gene. Mol Cancer 9:190
15. Li LC, Dahiya R (2002) MethPrimer: designing primers for methylation PCRs. Bioinformatics 18:1427-1431
16. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG (1999) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59:793-797
17. Carlson MR, Pope WB, Horvath S, Braunstein JG, Nghiemphu P, Tso CL, Mellinghoff I, Lai A, Liau LM, Mischel PS, Dong J, Nelson SF, Cloughesy TF (2007) Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. Clin Cancer Res 13:2592-2598
18. Lamber EP, Horwitz AA, Parvin JD (2010) BRCA1 represses amphiregulin gene expression. Cancer Res 70:996-1005
19. Shoyab M, McDonald VL, Bradley JG, Todaro GJ (1988) Amphiregulin: a bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human breast adenocarcinoma cell line MCF-7. Proc Natl Acad Sci USA 85:6528-6532
20. Mallakin A, Sugiyama T, Kai F, Taneja P, Kendig RD, Frazier DP, Maglic D, Matise LA, Willingham MC, Inoue K (2010) The Arf-inducing transcription factor Dmp1 encodes a transcriptional activator of amphiregulin, thrombospondin-1, JunB and Egr1. Int J Cancer 126:1403-1416
21. Busser B, Sancey L, Josserand V, Niang C, Favrot MC, Coll JL, Hurbin A (2010) Amphiregulin promotes BAX Inhibition and resistance to gefitinib in non-small-cell lung cancers. Mol Ther 18:528-535
22. Duhem-Tonnelle V, Bieche I, Vacher S, Loyens A, Maurage C-A, Collier F, Baroncini M, Blond S, Prevot V, Sharif A (2010) Differential distribution of erbB receptors in human glioblastoma multiforme: expression of erbB3 in CD133-positive putative cancer stem cells. J Neuropathol Exp Neurol 69:606-622
23. Yamashita S, Tsujino Y, Moriguchi K, Tatematsu M, Ushijima T (2006) Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2′-deoxycytidine treatment and oligonucleotide microarray. Cancer Sci 97:64-71
24. Shih IM, Chen L, Wang CC, Gu J, Davidson B, Cope L, Kurman RJ, Xuan J, Wang TL (2010) Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis. Am J Obstet Gynecol 203:584
25. Liang G, Gonzales FA, Jones PA, Orntoft TF, Thykjaer T (2002) Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2′-deoxycytidine. Cancer Res 62:961-966
26. Cillo C, Cantile M, Faiella A, Boncinelli E (2001) Homeobox genes in normal and malignant cells. J Cell Physiol 188:161-169
27. Whitcomb BP, Mutch DG, Herzog TJ, Rader JS, Gibb RK, Goodfellow PJ (2003) Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma. Clin Cancer Res 9:2277-2287
28. Fiegl H, Windbichler G, Mueller-Holzner E, Goebel G, Lechner M, Jacobs IJ, Widschwendter M (2008) HOXA11 DNA methylationtion-a novel prognostic biomarker in ovarian cancer. Int J Cancer 123:725-729
29. Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, de Tribolet N, Regli L, Wick W, Kouwenhoven MCM, Hainfellner JA, Heppner FL, Dietrich PY, Zimmer Y, Cairncross JG, Janzer RC, Domany E, Delorenzi M, Stupp R, Hegi ME (2008) Stem cell related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 26:3015-3024
30. Di Vinci A, Casciano I, Marasco E, Banelli B, Ravetti G, Borzi L, Brigati C, Forlani A, Dorcaratto A, Allemanni G, Zona G, Spaziante R, Gohlke H, Gardin G, Merlo D, Mantovani V, Romani M (2012) Quantitative methylation analysis of HOXA3,7,9 and 10 genes in glioma: association with tumor WHO grade and clinical outcome. J Cancer Res Clin Oncol 138:35-47
31. Qu X, Zhai Y, Wei H, Zhang C, Xing G, Yu Y, He F (2002) Characterization and expression of three novel differentiation-related genes belong to the human NDRG gene family. Mol Cell Biochem 229:35-44
32. Deng Y, Yao L, Chau L, Ng SS, Peng Y, Liu X, Au WS, Wang J, Li F, Ji S, Han H, Nie X, Li Q, Kung HF, Leung SY, Lin MC (2003) N-Myc downstream-regulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation. Int J Cancer 106:342-347
33. Feng L, Xie Y, Zhang H, Wu Y (2011) Down-regulation of NDRG2 gene expression in human colorectal cancer involves promoter methylation and microRNA-650. Biochem Biophys Res Commun 406:534-538
34. Furuta H, Kondo Y, Nakahata S, Hamasaki M, Sakoda S, Morishita K (2010) NDRG2 is a candidate tumor-suppressor for oral squamous-cell carcinoma. Biochem Biophys Res Commun 391:1785-1791
35. Lee DC, Kang YK, Kim WH, Jang YJ, Kim DJ, Park IY, Sohn BH, Sohn HA, Lee HG, Lim JS, Kim JW, Song EY, Kim DM, Lee MN, Oh GT, Kim SJ, Park KC, Yoo HS, Choi JY, Yeom YI (2008) Functional and clinical evidence for NDRG2 as a candidate suppressor of liver cancer metastasis. Cancer Res 68:4210-4220
36. Lusis EA, Watson MA, Chicoine MR, Lyman M, Roerig P, Reifenberger G, Gutmann DH, Perry A (2005) Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res 65:7121-7126
37. Li L, Wang J, Shen X, Wang L, Li X, Liu Y, Shi M, Zhao G, Deng Y (2011) Expression and prognostic value of NDRG2 in human astrocytomas. J Neurol Sci 308:77-82
38. Li W, Chu D, Chu X, Meng F, Wei D, Li H, Sun B (2011) Decreased expression of NDRG2 is related to poor overall survival in patients with glioma. J Clin Neurosci 18:1534-1537
39. Martinez R, Esteller M (2010) The DNA methylome of glioblastoma multiforme. Neurobiol Dis 39:40-46